


### REMARKS

Claims 5-14, 30, 33 and 44-52 are currently pending. Claims 1-4, 15-29, 31-32 and 34-43 have been canceled without prejudice or disclaimer, as being drawn to non-elected inventions. Claims 5, 9 and 10 have been amended and new claims 44-52 have been added. Support for the amendment to claims 5, 9 and 10 can be found in claim 5 as originally filed. Support for new claims 44-52 can be found at, *e.g.*, page 16, lines 11-21, Table 8, and claims 30 and 33 as originally filed. No new matter has been added by these amendments.

### CONCLUSION

Applicants respectfully submit that the present application claims a single invention which could not be properly further restricted. If there are any questions regarding these amendments and remarks, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Dated: January 21, 2003



Ivor R. Elrifi, Reg. No. 39,529

Naomi S. Biswas, Reg. No. 38,384

c/o MINTZ, LEVIN, COHN, FERRIS  
GLOVSKY AND POPEO, P.C.

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000

Fax: (617) 542-2241

## Version Marked to Show Amendments

### *In the claims:*

5. (Amended) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of:
- a) a mature form of the amino acid sequence given SEQ ID NO: [2, 4, 6,] 8[, 10, 12, 14, 16, 18, 20, or 22];
  - b) a variant of a mature form of the amino acid sequence [selected from the group consisting] of SEQ ID NO: [2, 4, 6,] 8[, 10, 12, 14, 16, 18, 20, or 22] wherein any amino acid in the mature form of the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed;
  - c) the amino acid sequence [selected from the group consisting] of SEQ ID NO: [2, 4, 6,] 8[, 10, 12, 14, 16, 18, 20, or 22];
  - d) a variant of the amino acid sequence [selected from the group consisting] of SEQ ID NO: [2, 4, 6,] 8[, 10, 12, 14, 16, 18, 20, or 22,] in which any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed;
  - e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising the amino acid sequence [selected from the group consisting] of SEQ ID NO: [2, 4, 6,] 8[, 10, 12, 14, 16, 18, 20, or 22] or any variant of said polypeptide wherein any amino acid of the chosen sequence is changed to a different amino acid, provided that no more than 10% of the amino acid residues in the sequence are so changed; and
  - f) the complement of any of said nucleic acid molecules.
9. (Amended) The nucleic acid molecule of claim 5, wherein said nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of
- a) the nucleotide sequence [selected from the group consisting] of SEQ ID NO: [1, 3, 5,] 7[, 9, 11, 13, 15, 17, 19 or 21];

- b) a nucleotide sequence wherein one or more nucleotides in the nucleotide sequence [selected from the group consisting] of SEQ ID NO: [1, 3, 5,] 7[, 9, 11, 13, 15, 17, 19 or 21] is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed;
  - c) a nucleic acid fragment of the sequence [selected from the group consisting] of SEQ ID NO: [1, 3, 5,] 7[, 9, 11, 13, 15, 17, 19 or 21]; and
  - d) a nucleic acid fragment wherein one or more nucleotides in the nucleotide sequence [selected from the group consisting] of SEQ ID NO: [1, 3, 5,] 7[, 9, 11, 13, 15, 17, 19 or 21] is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed.
10. (Amended) The nucleic acid molecule of claim 5, wherein said nucleic acid molecule hybridizes under stringent conditions to the nucleotide sequence of SEQ ID NO: [1, 3, 5,] 7[, 9, 11, 13, 15, 17, 19 or 21,] or a complement of said nucleotide sequence.
44. (New) An isolated nucleic acid molecule comprising nucleotides 38-1717 of SEQ ID NO: 7.
- 45 (New) A pharmaceutical composition comprising the nucleic acid molecule of claim 44 and a pharmaceutically acceptable carrier.
46. (New) A kit comprising in one or more containers, the pharmaceutical composition of claim 45.
47. (New) An isolated nucleic acid molecule comprising nucleotides 382-631 of SEQ ID NO: 7.
- 48 (New) A pharmaceutical composition comprising the nucleic acid molecule of claim 47 and a pharmaceutically acceptable carrier.

49. (New) A kit comprising in one or more containers, the pharmaceutical composition of claim 48.
50. (New) (New) An isolated nucleic acid molecule comprising nucleotides 970-1525 of SEQ ID NO: 7.
- 51 (New) A pharmaceutical composition comprising the nucleic acid molecule of claim 50 and a pharmaceutically acceptable carrier.
52. (New) A kit comprising in one or more containers, the pharmaceutical composition of claim 51.

TRA 1755257v1